4579 RaQualia Pharma Inc.ラクオリア創薬TSE Growth / Pharmaceuticals
0 posts
RaQualia Pharma Inc. (4579) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
RaQualia Pharma Inc. (4579) Stock Price History
RaQualia Pharma Inc. closed at ¥740 on Nov 20, 2026, +23.1% over 1 month, +2.8% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥123,128 today (+23.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +23.1%.
Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥740 | +12 | +1.65% |
| Nov 19 (Thu) | ¥728 | +9 | +1.25% |
| Nov 18 (Wed) | ¥719 | −24 | −3.23% |
| Nov 17 (Tue) | ¥743 | +5 | +0.68% |
| Nov 16 (Mon) | ¥738 | +92 | +14.24% |
| Nov 13 (Fri) | ¥646 | −21 | −3.15% |
| Nov 12 (Thu) | ¥667 | −12 | −1.77% |
| Nov 11 (Wed) | ¥679 | +14 | +2.11% |
| Nov 10 (Tue) | ¥665 | +15 | +2.31% |
| Nov 9 (Mon) | ¥650 | +77 | +13.44% |
If you had invested ¥100,000 3 months ago, it would be worth ¥126,280 today (+26.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +26.3%.
Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥740 | +12 | +1.65% |
| Nov 19 (Thu) | ¥728 | +9 | +1.25% |
| Nov 18 (Wed) | ¥719 | −24 | −3.23% |
| Nov 17 (Tue) | ¥743 | +5 | +0.68% |
| Nov 16 (Mon) | ¥738 | +92 | +14.24% |
| Nov 13 (Fri) | ¥646 | −21 | −3.15% |
| Nov 12 (Thu) | ¥667 | −12 | −1.77% |
| Nov 11 (Wed) | ¥679 | +14 | +2.11% |
| Nov 10 (Tue) | ¥665 | +15 | +2.31% |
| Nov 9 (Mon) | ¥650 | +77 | +13.44% |
If you had invested ¥100,000 6 months ago, it would be worth ¥133,094 today (+33.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved +33.1%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥740 | +16.0% |
| Oct 2026 | ¥638 | +2.9% |
| Sep 2026 | ¥620 | +9.5% |
| Aug 2026 | ¥566 | +17.4% |
| Jul 2026 | ¥482 | +1.9% |
| Jun 2026 | ¥473 | −5.6% |
| May 2026 | ¥501 | −35.9% |
If you had invested ¥100,000 1 year ago, it would be worth ¥102,778 today (+2.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved +2.8%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥740 | +16.0% |
| Oct 2026 | ¥638 | +2.9% |
| Sep 2026 | ¥620 | +9.5% |
| Aug 2026 | ¥566 | +17.4% |
| Jul 2026 | ¥482 | +1.9% |
| Jun 2026 | ¥473 | −5.6% |
| May 2026 | ¥501 | −35.9% |
| Apr 2026 | ¥781 | +0.4% |
| Mar 2026 | ¥778 | −22.7% |
| Feb 2026 | ¥1,007 | −0.8% |
| Jan 2026 | ¥1,015 | +0.5% |
| Dec 2025 | ¥1,010 | +11.7% |
| Nov 2025 | ¥904 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥91,245 today (−8.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −8.8%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥740 | −26.7% |
| 2025 | ¥1,010 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥80,087 today (−19.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −19.9%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥740 | −26.7% |
| 2025 | ¥1,010 | ― |
If you had invested ¥100,000 in Aug 2011, it would be worth ¥92,500 today (−7.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +548.7%, while this stock moved −7.5%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥740 | −26.7% |
| 2025 | ¥1,010 | +163.0% |
| 2024 | ¥384 | −44.2% |
| 2023 | ¥688 | −44.2% |
| 2022 | ¥1,232 | +4.9% |
| 2021 | ¥1,174 | +17.4% |
| 2020 | ¥1,000 | −25.4% |
| 2019 | ¥1,341 | +24.5% |
| 2018 | ¥1,077 | −54.2% |
| 2017 | ¥2,350 | +493.4% |
| 2016 | ¥396 | +17.9% |
| 2015 | ¥336 | −23.6% |
| 2014 | ¥440 | −35.4% |
| 2013 | ¥681 | +95.7% |
| 2012 | ¥348 | −42.0% |
| 2011 | ¥600 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Aug 2011). Please check the latest prices before trading.
RaQualia Pharma Inc. (4579) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of RaQualia Pharma Inc. (4579)
Business overview
Together with two consolidated subsidiaries, the company is an R&D-driven drug discovery venture aiming to create new drugs for disease areas with high medical needs using advanced science and technology, and it has a single segment. Its basic business is earning revenue by licensing out the intellectual property rights of development compounds it has created to pharmaceutical companies and others. In January 2026 it absorbed subsidiary 「テムリック」. As success rates for new drug development fall and costs rise, pharmaceutical companies are actively bringing in high-quality development compounds from outside, and in the United States about 60% of new drugs are said to originate from biotech ventures. Beyond its own R&D, the company is deepening cooperation with academia, startups and others to build a next-generation drug discovery value chain.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 2.49x | Above the sector median of 1.86x (No. 51 from the lowest) |
|---|---|---|
| ROE | -0.87% | No. 35 in the sector (highest first); median 4.17% |
| Market cap | ¥19.3 bn | No. 39 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥1,429 | 2025/12/8 |
|---|---|---|
| 52-week low | ¥453 | 7/29 |
| Current position | 29.4% | Where the low is 0% and the high is 100% (close on 11/20: ¥740) |
| Year to date | -26.7% | No. 50 of 77 in the sector (best first) |
| 1 year | +2.8% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 2 times | Latest: 11/16 (No. 25) |
|---|
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/17 15:30胃酸分泌抑制剤tegoprazanのブラジルにおける販売承認に関するお知らせ
- 11/13 15:302026年12月期 第3四半期決算短信〔日本基準〕(連結)
- 11/13 15:30決算説明会資料 2026年12月期(第19期) 第3四半期
- 10/21 15:30新規ナトリウムチャネル遮断薬の第II相臨床試験開始に伴う一時金受領のお知らせ
Filings from the past 12 months (4).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.